Pfizer Archives - CFO

CFOs On the Move: Week Ending November 19

CFOs On the Move: Week Ending November 19

Workday, Canopy Growth, Poshmark, Continental AG, CBE Companies, MultiPlan, CMC Materials, Omnipresent, Pfizer

By Vincent Ryan | November 19, 2021

Frank D’Amelio to Step Down as Pfizer CFO

Frank D’Amelio to Step Down as Pfizer CFO

During his 14-year tenure, D'Amelio played a key role in transforming Pfizer into "an industry leading, science-based biopharmaceutical company."

By Matthew Heller | November 18, 2021

Merck Drops Out of COVID-19 Vaccine Race

Risk & Compliance

Merck Drops Out of COVID-19 Vaccine Race

Merck's announcement that it is shelving its two vaccine candidates "marks a shocking setback for one of the most storied vaccine makers."

By Matthew Heller | January 25, 2021

Early Analysis Shows Pfizer COVID-19 Vaccine 90% Effective

Risk & Compliance

Early Analysis Shows Pfizer COVID-19 Vaccine 90% Effective

The company said 50 million doses of its two-shot vaccine could be available globally by the end of 2020.

By Lauren Muskett | November 9, 2020

Pfizer, BioNTech to Supply U.S. Government Up to 600M Doses of Coronavirus Vaccine

Risk & Compliance

Pfizer, BioNTech to Supply U.S. Government Up to 600M Doses of Coronavirus Vaccine

The initial 100 million doses ordered is valued at $1.95 billion.

By Lauren Muskett | July 22, 2020

Pfizer and Mylan to Combine Off-Patent Drugs Businesses

Pfizer and Mylan to Combine Off-Patent Drugs Businesses

The combined company, which will sell Mylan’s EpiPen and Pfizer’s Viagra, could draw annual sales of more than $20 billion.

By Lauren Muskett | July 29, 2019

Pfizer Beats Estimates on Strength in Key Drugs

Financial Performance

Pfizer Beats Estimates on Strength in Key Drugs

Sales from Pfizer's innovative health division were particularly strong in the second quarter, with anti-smoking drug Chantix up 8% to $8.2 billion.

By Matthew Heller | July 31, 2018

Pfizer to Split Into Three Units

Pfizer to Split Into Three Units

The company also announced it would defer drug price hikes, following pressure from President Donald Trump.

By William Sprouse | July 11, 2018

Pfizer Q4 Profit Surges to $12B But Shares Fall

Pfizer Q4 Profit Surges to $12B But Shares Fall

The 3% drop in the share price appears to reflect the company's estimate of a 2018 tax rate of 17%, which is higher than investors anticipated.

By Matthew Heller | January 30, 2018

Generic Competition Hits Pfizer’s Q2 Sales

Financial Performance

Generic Competition Hits Pfizer’s Q2 Sales

The drug maker cites headwinds from losses of market exclusivity for the 14% drop in Essential Health revenues.

By Matthew Heller | August 2, 2017

What Makes for a Public-Company CFO?

What Makes for a Public-Company CFO?

Five top finance chiefs tell how they got where they are, and what their potential successors need to do.

By David McCann | May 31, 2017

Pfizer Makes Cancer Play With Medivation Deal

Pfizer Makes Cancer Play With Medivation Deal

The $14 billion acquisition would add the best-selling prostate cancer drug Xtandi to Pfizer's growing oncology portfolio.

By Matthew Heller | August 22, 2016

Ex-Pfizer Employee Accused of Insider Trading

Risk & Compliance

Ex-Pfizer Employee Accused of Insider Trading

Michael Maciocio allegedly misused confidential information about potential Pfizer deals to make trades himself and tip off a stockbroker friend.

By Matthew Heller | June 3, 2016

Pfizer Adds Eczema Gel With $5B Anacor Deal

Pfizer Adds Eczema Gel With $5B Anacor Deal

If Anacor's treatment for eczema is approved by the FDA, Pfizer predicts peak-year sales could exceed $2 billion.

By Katie Kuehner-Hebert | May 16, 2016

Finance Roundup for Executives

Corporate Finance

Finance Roundup for Executives

Be informed, get involved, and shape the world through finance. Read CFO.com's most recent headlines and standout stories.

By Kerry Maruna | April 7, 2016